PARIS and GRENOBLE, FRANCE - October 21st, 2021 - LXRepair, a pioneer in personalized radiotherapy with functional assays measuring DNA repair to predict treatment response, with a clinical proof-of-concept of radiotoxicity prediction in breast and prostate cancer, and Gustave Roussy, Europe's leading cancer center, announced today the launch of a joint laboratory to improve the personalization of radiotherapy.

· This joint laboratory, named RADIO CARE, is recipient of the LABCOM program from the French National Research Agency (ANR).
· The goal of the RADIO CARE laboratory is to leverage on LXRepair's technologies to:
· develop clinical proof of concept and products in new indications using radiotherapy
· extend the test to tumor response prediction and chemotherapy.

Gustave Roussy and LXRepair are joining forces to set up the RADIO CARE laboratory. This partnership is built on two driving forces: the cancer radiotherapy expertise of Gustave Roussy and the DNA repair assay platform developed by LXRepair.

"Radiotherapy, which is the second most frequent curative treatment after surgery, has gained a high level of precision from a technological side, but is lagging in terms of personalization of the treatment. Indeed, individual hypersensitivity which can be associated with severe toxicities detrimental to the patient, is not currently assessed due to the lack of relevant and easy-to-use assays in a clinical setting. This partnership with LXRepair is key to exploit the results of our translational research in radiotherapy and ultimately improve patient care with predictive diagnostic assays", explains Prof. Eric Deutsch, radiation oncologist and head of the Department of Radiotherapy at Gustave Roussy, head of the Inserm 1030 joint research unit and professor of oncology-radiotherapy at the Université Paris-Saclay.

"Making our assays available to oncologists for the global monitoring of a set of enzymatic biomarkers of DNA repair from a blood sample meets an important medical need. The result of our proprietary assays is a functional signature that predicts the efficacy or toxicity of a treatment. We have reached a turning point in the quest of radiotherapy personalization and this collaboration with Prof. Eric Deutsch highlights the high expectations in the clinic. RADIO CARE is a unique opportunity to accelerate the shift to personalized radiotherapy and is a great honour", adds Sylvie Sauvaigo, PhD, president and chief scientific officer of LXRepair.

"This partnership is a strategic alliance between Gustave Roussy and LXRepair to address a real medical need. For LXRepair, it is a new step towards the adoption of our technology by oncologists and the validation of clinical biomarkers, beyond the breast and prostate cancer indications which are already in the clinical validation phase, and for which the launch of the Safer RAD-LX kit is planned for 2024," concludes Stéphane Altaba, chief executive officer of LXRepair


About LXRepair
LXREPAIR is a biotech company developing in vitro diagnostic (IVD) assays to predict cancer therapy outcomes. Its innovative assays are based on functional signatures of DNA repair biomarkers that can be detected on a biochip, from a blood sample or a tumor biopsy. In contrast to the genomic approach, the functional approach captures the actual activity DNA repair mechanisms. This approach makes LXRepair's assays more relevant and actionable than other non-functional DNA repair assays. This diagnostic information will enable the oncologist to personalize the patient's radiation or chemotherapy treatment.

About Gustave Roussy
Ranked first in Europe and fifth in the world in the fight against cancer, Gustave Roussy is a global center of expertise entirely dedicated to cancer patients. The Institute is a founding pillar of the Paris Saclay Cancer Cluster. A source of therapeutic innovations and diagnostic advances, the Institute treats nearly 50,000 patients each year and develops an integrated approach between research, care and teaching.